Status:
COMPLETED
Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced Ejection Fraction
Lead Sponsor:
Italian Society of Cardiology
Collaborating Sponsors:
Università degli Studi di Brescia
Federico II University
Conditions:
Heart Failure, Left Sided
Left Ventricular Dysfunction
Eligibility:
All Genders
18+ years
Brief Summary
This prospective study evaluates the mechanisms of benefit of sacubitril/valsartan in a population of outpatients with heart failure with reduced ejection fraction, to investigate the relationship bet...
Detailed Description
Therapeutic interventions were made according to a titration protocol in stable optimal medical therapy. Therapy with sacubitril/valsartan was introduced after a 48-hour wash-out of an ACE inhibitor o...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA
- Ambulatory patients on stable optimal medical therapy
- History of HF and LVEF ≤ 40%
- II-III NYHA class
- EXCLUSION CRITERIA
- History of congenital heart disease
- Severe valvular disease or valvular surgery
- Recent acute coronary syndromes or stroke
- Poor acoustic windows or missing data.
- Death or uncompleted follow-up evaluation
- Cardiac surgery interventions
- Cardiac resynchronization therapy
- Coronary or mitral interventions
Exclusion
Key Trial Info
Start Date :
January 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 16 2020
Estimated Enrollment :
652 Patients enrolled
Trial Details
Trial ID
NCT04397302
Start Date
January 13 2019
End Date
March 16 2020
Last Update
May 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Frank Lloyd Dini
Pisa, Italy, 56124